IBJNews

Lilly, Roche dive deep into diagnostics

Back to TopCommentsE-mailPrintBookmark and Share

Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic tests to gin up more sales.

Lilly, which launched its own diagnostic division last month to focus on cancer and Alzheimer’s drugs, has also found a test that could help its slow-selling blood thinner, Effient.

Indianapolis-based Lilly said Monday that its sales reps will talk up to doctors a blood test made by a San Diego firm that measures the clotting ability of each patient’s blood after taking a blood thinner. From Lilly’s standpoint, the idea is to identify which patients aren’t benefiting from Effient’s main competitor, Plavix.

Plavix’s annual sales of $9.5 billion dwarf those of Effient—$35 million in its first nine months on the market. But studies have shown that genetic variations cause as many as 14 percent of Plavix patients to receive little or no anti-clotting benefit from the drug.

Both Effient and Plavix are given to patients who have had their arteries propped open through balloon angioplasties or stents.

The diagnostic blood test, made by Accumetrics Inc., costs about $60, according to The New York Times. That’s cheaper and faster than a genetic test that could determine which patients won’t respond well to Plavix.

"We believe physicians will want to know the specific effect of a patient's antiplatelet [blood thinning] therapy and whether additional measures may be needed," said Dr. Rogelio Braceras, senior medical director of thrombosis at Lilly's development partner on Effient, Japan-based Daiichi Sankyo Inc.

Switzerland-based Roche, which operates both drug and diagnostic businesses, is testing one of its diagnostic tests against traditional Pap smears to see which detects the precursor of cervical cancer earliest. Roche Diagnostics' U.S. headquarters is in Indianapolis.

On July 9, Roche announced results of a clinical trial that showed its test, the cobas 4800 HPV Test, said one in 10 women who had the precursor to cervical cancer, the human papillomavirus, did not test positive for cancer in a Pap smear.

Roche’s test could potentially help sales of its blockbuster cancer drug Avastin. The drug is approved to treat various forms of cancer, and recent studies have examined it as a possible treatment for cervical cancer. Doctors have freedom to prescribe it for any treatment regimen.

Expect a lot more of these efforts in the future. An October study by consulting firm PricewaterhouseCoopers estimates the drug, device and diagnostic market at $24 billion a year and growing at 10 percent each of the next five years.

“This is kind of the next step,” said Tiffany Olson, Lilly’s vice president of diagnostics, in an interview at Lilly’s corporate headquarters south of downtown. “It’s making the promise actionable: right patient, right time, right dose."
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT